Annexon (NASDAQ:ANNX) Research Coverage Started at Citizens Jmp

Posted by Brenda Bartman on Jul 24th, 2026

Citizens Jmp began coverage on shares of Annexon (NASDAQ:ANNX – Free Report) in a report issued on Tuesday morning, MarketBeat.com reports. The firm issued a market underperform rating and a $3.00 price target on the stock.

Other research analysts have also recently issued research reports about the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a report on Monday, July 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Annexon in a research report on Friday, July 17th. The Goldman Sachs Group started coverage on shares of Annexon in a research note on Tuesday, May 12th. They issued a “neutral” rating and a $7.00 target price for the company. Citigroup began coverage on Annexon in a report on Tuesday. They set a “market underperform” rating for the company. Finally, Needham & Company LLC boosted their price target on Annexon from $11.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $15.33.

Get Our Latest Analysis on Annexon

Annexon Price Performance

NASDAQ:ANNX opened at $5.30 on Tuesday. Annexon has a fifty-two week low of $2.03 and a fifty-two week high of $7.18. The stock has a market capitalization of $868.35 million, a PE ratio of -4.34 and a beta of 1.16. The business’s 50-day simple moving average is $5.36 and its 200-day simple moving average is $5.59.

Annexon (NASDAQ:ANNX – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.07. On average, research analysts expect that Annexon will post -0.92 earnings per share for the current year.

Insiders Place Their Bets

In other Annexon news, Director Muneer A. Satter purchased 613,497 shares of the stock in a transaction on Thursday, May 28th. The shares were purchased at an average cost of $5.41 per share, for a total transaction of $3,319,018.77. Following the purchase, the director owned 10,342,134 shares of the company’s stock, valued at approximately $55,950,944.94. This represents a 6.31% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William H. Carson acquired 8,000 shares of Annexon stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $5.78 per share, with a total value of $46,240.00. Following the completion of the purchase, the director owned 78,405 shares in the company, valued at approximately $453,180.90. The trade was a 11.36% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.31% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. CIBC Bancorp USA Inc. acquired a new stake in shares of Annexon in the 3rd quarter valued at approximately $31,000. Engineers Gate Manager LP bought a new stake in Annexon during the second quarter worth $32,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Annexon by 65.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock valued at $35,000 after acquiring an additional 2,785 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new stake in Annexon in the fourth quarter valued at $50,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in shares of Annexon in the 4th quarter valued at about $52,000.

About Annexon

(Get Free Report)

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.